Amendment 1: DRIVe EZ Broad Agency Announcement

Office of Biomedical Advanced Research and Development
Authority (BARDA) Division of Research, Innovation & Ventures

(DRIVe)

Amendment 001 Issuance for Easy Broad Agency Announcement

(EZ-BAA) BAA-22-100-SOL-00003

The purpose of this Amendment is the following:
1) Add the descriptions of the following Areas of Interest

(AOIs):

AOI #15: ReDIRECT

AOI #16: Lab at Home
AOI #17: Digital MCMs
AOI #18: Host-Directed Therapeutics
AOI #19: Healing Lungs
AOI #20: DRIVe Forward
AOI #21: Vaccines on Demand
AOI #22: ReBoot
AOI #23: Host-Based Diagnostics

INTRODUCTION AND OVERVIEW INFORMATION

A. Development Opportunity Objective:

Under this Amendment, DRIVe is doing the following:
1)

Add the descriptions of the following research Areas of Interest (AOIs):

AOI #15: ReDIRECT

AOI #16: Lab at Home
AOI #17: Digital MCMs
AOI #18: Host-Directed Therapeutics
AOI #19: Healing Lungs
AOI #20: DRIVe Forward
AOI #21: Vaccines on Demand
AOI #22: ReBooT
AOI #23: Host-Based Diagnostics

We are seeking abstract submissions for the following AOI’s:

AOI #15: ReDIRECT

The availability of effective medical countermeasures (MCMs) against chemical threats is critical in the treatment of their acute health effects. Necessary attributes of effective MCMs against chemical threats include ease of administration during a mass-casualty situation and rapid efficacy as a post-exposure therapy. Drug repurposing is a strategy that is used to identify new uses, outside of their original clinical indication, for FDA approved or late-stage investigational therapeutics. The identification of existing compounds for repurposing as MCMs holds the potential to expand current response capabilities to chemical threats, as well as potentially mitigating the costs and risks associated with conventional drug discovery. BARDA is requesting abstract submissions for projects that repurpose existing therapeutics as MCMs against chemical threats (cyanide, opioids, nerve agents, chlorine, sulfur mustard, etc.). These therapeutics should have a strong mechanistic justification for potential use as MCMs. Ideal candidates for MCMs should have a known safety profile from previous clinical indications or development and be safe and effective for the entire population, including at-risk populations such as pediatrics, geriatrics, pregnant women, and immunocompromised individuals. MCM candidates should:
1. Already be approved or in clinical development for a conventional indication similar to the symptomology associated with exposure to a chemical agent; and